Focus Partners Advisor Solutions LLC Buys New Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Focus Partners Advisor Solutions LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 704 shares of the company’s stock, valued at approximately $234,000.

A number of other large investors have also recently bought and sold shares of the company. Voloridge Investment Management LLC boosted its position in Medpace by 55.9% in the fourth quarter. Voloridge Investment Management LLC now owns 164,208 shares of the company’s stock valued at $54,555,000 after buying an additional 58,861 shares during the last quarter. Worldquant Millennium Advisors LLC boosted its position in Medpace by 26.1% in the fourth quarter. Worldquant Millennium Advisors LLC now owns 4,981 shares of the company’s stock valued at $1,655,000 after buying an additional 1,031 shares during the last quarter. Woodline Partners LP purchased a new stake in Medpace in the fourth quarter valued at approximately $5,305,000. Vident Advisory LLC boosted its position in Medpace by 9.6% in the fourth quarter. Vident Advisory LLC now owns 4,716 shares of the company’s stock valued at $1,567,000 after buying an additional 412 shares during the last quarter. Finally, Sone Capital Management LLC purchased a new stake in Medpace in the fourth quarter valued at approximately $1,318,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares of the company’s stock, valued at approximately $904,856.36. This represents a 36.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.30% of the stock is owned by corporate insiders.

Medpace Price Performance

Shares of MEDP stock opened at $294.89 on Monday. The company has a market cap of $8.48 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 3.81 and a beta of 1.55. The stock has a 50 day simple moving average of $301.83 and a 200-day simple moving average of $326.59. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million for the quarter, compared to analysts’ expectations of $528.38 million. During the same period in the previous year, the firm posted $3.20 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Truist Financial dropped their target price on Medpace from $333.00 to $300.00 and set a “hold” rating on the stock in a research report on Wednesday, April 23rd. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective on the stock. Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. TD Cowen lowered Medpace from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Mizuho lowered their price objective on Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.